In sum, these results indicated functional activity of combined alisertib/FRAX1036 in xenografts, reflected in decreased tumor volume, reduced cellularity, suppressed Ki67, altered cell cycle checkpoints, and depressed ERα signaling. The gene discussed is ESR1; the disease is neoplasm.